MAPT and oculocutaneous albinism type 1: Table S1 shows demographic features of the 1548 clinically normal MCSA individuals with amyloid PET and MRI but not tau PET that were used to constrain or stabilize ATN prevalence estimates among the subset of 435 who had amyloid PET, MRI and tau PET.